Dataset Information

The clinical performance evaluation of novel protein chips for eleven biomarkers detection and the diagnostic model study.

ABSTRACT: We aimed to develop and validate two novel protein chips, which are based on microarray chemiluminescence immunoassay and can simultaneously detected 11 biomarkers, and then to evaluate their clinical diagnostic value by comparing with the traditional methods. Protein chips were evaluated for limit of detection, specificity, common interferences, linearity, precision and accuracy. 11 biomarkers were simultaneously detected by traditional methods and protein chips in 3683 samples, which included 1723 cancer patients, 1798 benign diseases patients and 162 healthy controls. After assay validation, protein chips demonstrated high sensitivity, high specificity, good linearity, low imprecision and were free of common interferences. Compared with the traditional methods, protein chips have good correlation in the detection of all the 13 kinds of biomarkers (r?0.935, P<0.001). For specific cancer detection, there were no statistically significant differences between the traditional method and novel protein chips, except that male protein chip showed significantly better diagnostic value on NSE detection (P=0.004) but significantly worse value on pro-GRP detection (P=0.012), female chip showed significantly better diagnostic value on pro-GRP detection (P=0.005). Furthermore, both male and female multivariate diagnostic models had significantly better diagnostic value than single detection of PGI, PG II, pro-GRP, NSE and CA125 (P<0.05). In addition, male models had significantly better diagnostic value than single CA199 and free-PSA (P<0.05), while female models observed significantly better diagnostic value than single CA724 and ?-HCG (P<0.05). For total disease or cancer detection, the AUC of multivariate logistic regression for the male and female disease detection was 0.981 (95% CI: 0.975-0.987) and 0.836 (95% CI: 0.798-0.874), respectively. While, that for total cancer detection was 0.691 (95% CI: 0.666-0.717) and 0.753 (95% CI: 0.731-0.775), respectively. The new designed protein chips are simple, multiplex and reliable clinical assays and the multi-parameter diagnostic models based on them could significantly improve their clinical performance.

SUBMITTER: Luo Y

PROVIDER: S-EPMC4723802 | biostudies-other | 2015

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

The clinical performance evaluation of novel protein chips for eleven biomarkers detection and the diagnostic model study.

Luo Yuan Y Zhu Xu X Zhang Pengjun P Shen Qian Q Wang Zi Z Wen Xinyu X Wang Ling L Gao Jing J Dong Jin J Yang Caie C Wu Tangming T Zhu Zheng Z Tian Yaping Y

International journal of clinical and experimental medicine 20151115 11

We aimed to develop and validate two novel protein chips, which are based on microarray chemiluminescence immunoassay and can simultaneously detected 11 biomarkers, and then to evaluate their clinical diagnostic value by comparing with the traditional methods. Protein chips were evaluated for limit of detection, specificity, common interferences, linearity, precision and accuracy. 11 biomarkers were simultaneously detected by traditional methods and protein chips in 3683 samples, which included ...[more]

PMID: 26884957

Similar Datasets

Project description:Ultrafast, portable, and inexpensive molecular diagnostic platforms are critical for clinical diagnosis and on-site detection. There are currently no available real-time polymerase chain reaction (PCR) devices able to meet the demands of point-of-care testing, as the heating and cooling processes cannot be avoided. In this study, the dual temperature modules were first designed to process microfluidic chips automatically circulating between them. Thus, a novel ultrafast molecular diagnostic real-time PCR device (approximately 18 and 23 min for DNA and RNA detection, respectively) with two channels (FAM and Cy5) for the detection of 12 targets was developed. The device contained three core functional components, including temperature control, optics, and motion, which were integrated into a portable compact box. The temperature modules accurately control temperature in rapid thermal cycles with less than ±0.1 °C, ±1 °C and ±0.5 °C for the temperature fluctuation, uniformity, and error of indication, respectively. The average coefficient of variation (CV) of the fluorescence intensity (FI) for all 12 wells was 2.3% for FAM and 2.7% for Cy5. There was a good linear relationship between the concentrations of fluorescent dye and the FIs of FAM and Cy5(R 2 = 0.9990 and 0.9937), and the average CVs of the Ct values calculated by the embedded software were 1.4% for FAM and Cy5, respectively. The 100 double-blind mocked sputum and 249 clinical stool samples were analyzed by the ultrafast real-time PCR device in comparison with the DAAN Gene SARS-CoV-2 kit run on the ABI 7500 instrument and Xpert C. difficile/Epi, respectively. Among the 249 stool samples, the ultrafast real-time PCR device detected toxigenic C. difficile in 54 samples (54/249, 21.7%) with a specificity and positive predictive values of 99.0 and 96.3%, which were higher than the Xpert C. difficile/Epi values of 94.4 and 88.1% (p > 0.05). The ultrafast real-time PCR device detected 15 SARS-CoV-2 positive samples, which has a 100% concordance with that obtained by the DAAN Gene SARS-CoV-2 kit. This study demonstrated that the ultrafast real-time PCR device integrated with microfluidic chips and dual temperature modules is an ultrafast, reliable, easy-to-use, and cost-effective molecular diagnostic platform for clinical diagnosis and on-site testing, especially in resource-limited settings.

Project description:Interventions: This prospective, cross-sectional, multi-centre, blinded clinical trial evaluates the performance of the ColoSTAT as an in vitro diagnostic test (IVD) for the early detection of colorectal cancer. Participants will be recruited from two cohorts: Chort 1, patients recently diagnosed via colonoscopy with colorectal cancer who are progressing to colorectal surgery or neoadjuvant treatment as part of their normal standard of care; Cohort 2, patients with no prior history of colorectal cancer who have been referred for colonoscopy by their consulting physician. Participants will be asked to donate around 18 mL of blood for use in the ColoSTAT test. Further, if they do not have a valid result from a faecal immunochemical test (FIT) completed within the preceding 6 months, participants will be asked to complete a FIT sample collection using a commercial FIT home collection kit (provided) and return the samples to the study site for shipment to a central laboratory for testing . Physically, participation in the trial will involve collection of the blood sample for the ColoSTAT test, completion of a home FIT sample collection if needed and return of the completed kit to the the study site. Additionally, information that will be collected at that first visit will comprise: Details of smoking status and age (known risk factors for colorectal cancer), any personal and/or family medical history of colorectal cancer, results from a FIT performed within the previous 6 months and a listing of any concomitant medications. Vital signs, including height, weight, waist circumference, body mass index, blood pressure and heart rate will also be collected and reported. This first Visit is expected to take around 1-2 hour to complete. Sometime during the period Day 10 through 28 Primary outcome(s): Assessment of the sensitivity of ColoSTAT for detection of colorectal cancers compared with the gold standard - colonoscopy. This is calculated as the % of true colorectal cancers (as defined by colonoscopy) that are correctly classified by the ColoSTAT test. [One year from commencement of recruitment.];Assessment of the specificity of ColoSTAT for detection of colorectal cancers compared with the gold standard - colonoscopy. This is calculated as the % of true cancer-negative participants (as defined by colonoscopy) that are correctly classified as negative by the ColoSTAT test.[One year after commencement of recruitment] Study Design: Purpose: Diagnosis; Allocation: Non-randomised trial

Project description:ObjectiveTo determine whether the sensitivity and specificity of SNP chips are adequate for detecting rare pathogenic variants in a clinically unselected population.DesignRetrospective, population based diagnostic evaluation.Participants49 908 people recruited to the UK Biobank with SNP chip and next generation sequencing data, and an additional 21 people who purchased consumer genetic tests and shared their data online via the Personal Genome Project.Main outcome measuresGenotyping (that is, identification of the correct DNA base at a specific genomic location) using SNP chips versus sequencing, with results split by frequency of that genotype in the population. Rare pathogenic variants in the BRCA1 and BRCA2 genes were selected as an exemplar for detailed analysis of clinically actionable variants in the UK Biobank, and BRCA related cancers (breast, ovarian, prostate, and pancreatic) were assessed in participants through use of cancer registry data.ResultsOverall, genotyping using SNP chips performed well compared with sequencing; sensitivity, specificity, positive predictive value, and negative predictive value were all above 99% for 108 574 common variants directly genotyped on the SNP chips and sequenced in the UK Biobank. However, the likelihood of a true positive result decreased dramatically with decreasing variant frequency; for variants that are very rare in the population, with a frequency below 0.001% in UK Biobank, the positive predictive value was very low and only 16% of 4757 heterozygous genotypes from the SNP chips were confirmed with sequencing data. Results were similar for SNP chip data from the Personal Genome Project, and 20/21 individuals analysed had at least one false positive rare pathogenic variant that had been incorrectly genotyped. For pathogenic variants in the BRCA1 and BRCA2 genes, which are individually very rare, the overall performance metrics for the SNP chips versus sequencing in the UK Biobank were: sensitivity 34.6%, specificity 98.3%, positive predictive value 4.2%, and negative predictive value 99.9%. Rates of BRCA related cancers in UK Biobank participants with a positive SNP chip result were similar to those for age matched controls (odds ratio 1.31, 95% confidence interval 0.99 to 1.71) because the vast majority of variants were false positives, whereas sequence positive participants had a significantly increased risk (odds ratio 4.05, 2.72 to 6.03).ConclusionsSNP chips are extremely unreliable for genotyping very rare pathogenic variants and should not be used to guide health decisions without validation.

Dataset Information

The clinical performance evaluation of novel protein chips for eleven biomarkers detection and the diagnostic model study.

Publications

The clinical performance evaluation of novel protein chips for eleven biomarkers detection and the diagnostic model study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets